Altimmune (NASDAQ:ALT) Director Wayne Pisano Acquires 10,000 Shares of Company Stock

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) Director Wayne Pisano purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 13th. The stock was bought at an average price of $1.64 per share, for a total transaction of $16,400.00. Following the transaction, the director directly owned 58,800 shares of the company’s stock, valued at $96,432. This trade represents a 20.49% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Altimmune Price Performance

ALT stock traded up $0.04 during midday trading on Friday, reaching $1.65. The company had a trading volume of 3,528,857 shares, compared to its average volume of 3,885,901. Altimmune, Inc. has a 1-year low of $1.58 and a 1-year high of $6.44. The stock has a 50 day moving average price of $2.58 and a 200-day moving average price of $3.15. The company has a debt-to-equity ratio of 0.07, a current ratio of 26.78 and a quick ratio of 26.78. The company has a market capitalization of $319.99 million, a price-to-earnings ratio of -2.28 and a beta of 0.16.

Altimmune (NASDAQ:ALT – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Equities research analysts expect that Altimmune, Inc. will post -0.58 earnings per share for the current year.

Altimmune News Summary

These are some of the ALT news items that stood out recently:

  • Positive Sentiment: Newly published 48-week Phase 2b IMPACT results showed pemvidutide improved non-invasive measures of liver fat, inflammation, and fibrosis, alongside weight loss and generally favorable tolerability. The findings support the ongoing Phase 3 PERFORMA MASH trial, though pemvidutide remains investigational. Trial results article
  • Positive Sentiment: Altimmune reported $480 million in cash, equivalents, and investments at September 30, with a projected runway through 2029. Management also said the Phase 3 MASH program is progressing as planned and scheduled an FDA meeting on its alcohol-use-disorder program for December. Quarterly update
  • Negative Sentiment: A Seeking Alpha analysis characterized pemvidutide’s development as late and capital-intensive, underscoring the risk that lengthy trials and spending could weigh on ALT before any potential product revenue. Analysis

Hedge Funds Weigh In On Altimmune

Large investors have recently modified their holdings of the business. Nantahala Capital Management LLC boosted its holdings in Altimmune by 14.7% in the third quarter. Nantahala Capital Management LLC now owns 1,720,000 shares of the company’s stock valued at $4,919,000 after acquiring an additional 220,000 shares during the last quarter. R Squared Ltd lifted its stake in shares of Altimmune by 99.6% in the third quarter. R Squared Ltd now owns 26,475 shares of the company’s stock valued at $76,000 after buying an additional 13,211 shares in the last quarter. StoneX Group Inc. purchased a new position in shares of Altimmune during the third quarter valued at approximately $46,000. Parallel Advisors LLC increased its stake in Altimmune by 21,755.0% in the 3rd quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock valued at $25,000 after buying an additional 8,702 shares during the last quarter. Finally, Alps Advisors Inc. grew its position in Altimmune by 29.6% during the third quarter. Alps Advisors Inc. now owns 255,875 shares of the company’s stock valued at $732,000 after buying an additional 58,501 shares during the period. Institutional investors own 78.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ALT. B. Riley Financial reissued a “buy” rating on shares of Altimmune in a research note on Friday. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a report on Monday, September 21st. Wall Street Zen downgraded Altimmune from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Evercore reissued an “outperform” rating on shares of Altimmune in a report on Wednesday, September 23rd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.33.

Get Our Latest Analysis on Altimmune

About Altimmune

(Get Free Report)

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.

Featured Articles

Insider Buying and Selling by Quarter for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.